PATENT Atty. Docket No. 1155.005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Douglas J. Jolly et al.

Serial No.:

09/001,039

Group Art Unit: 1633

Filed:

January 13, 1998

Examiner: to be assigned

For:

METHODS FOR ADMINISTRATION OF RECOMBINANT GENE

DELIVERY VEHICLES FOR TREATMENT OF HEMOPHILIA AND

OTHER DISORDERS

DECLARATION UNDER 37 CFR §1.821(f) AND (g)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

I hereby state that the submission, filed in accordance with 37 C.F.R. §1.821(g) herein does not include new matter.

I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both (18 USC 1001), and may jeopardize the validity of the application or any patent issuing thereon.

By:

Paul B. Savereide, Ph.D.

Attorney for Applicants

Reg. No. 36,914

May 19, 1998

CHIRON CORPORATION Intellectual Property - R440 P.O. Box 8097 Emeryville, California 94662-8097 (510) 923-2585 - (510) 655-3542 (fax)

I hereby certify that this correspondence v heing deposited with the United States Postal Service as First Class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

S	
~	
9	
9	
98	
98	

Application No.: OENOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE